Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 11/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TACR2 | P21452 | 2/20 | 0.53 |
| ▸ | DHODH | Q02127 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7529838 | 0.81 | TACR3 (1.00) | TACR3TACR2CYP2D6CYP2C19 | |
| SCHEMBL7529842 | 0.81 | TACR3 (1.00) | TACR3TACR2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL4467638 | 0.81 | TACR3 (0.98) | TACR3KCNH2TACR2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL4467630 | 0.81 | TACR3 (0.98) | TACR3KCNH2TACR2CYP2D6CYP2C19 | |
| SCHEMBL4234246 | 0.80 | DHODH (0.57) | TACR3PDE10ATSHRTACR2DHODH | |
| SCHEMBL3959255 | 0.79 | TACR3 (0.68) | TACR3PDE10ATSHRTACR2DHODH | |
| SCHEMBL7532790 | 0.78 | TACR3 (0.47) | TACR3KCNH2PDE10ALMNACYP2D6 | |
| SCHEMBL27891977 | 0.78 | DHODH (0.55) | TACR3PDE10ATSHRTACR2DHODH | |
| SCHEMBL4665929 | 0.77 | TACR3 (0.64) | TACR3PDE10ATSHRTACR2DHODH | |
| SCHEMBL5498214 | 0.77 | PDE10A (0.62) | TACR3PDE10ATSHRDHODHLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096885-A1 | Quinoline Derivatives as Neurokinin Receptor Antagonists | MERCK SHARP & DOHME LTD. (GB) | 2008-04-24 | — | — | US | claimed |
| EP-1776344-A2 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2007-04-25 | — | — | EP | claimed |
| WO-2006013393-A2 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-02-09 | — | — | WO | claimed |
| US-20080096885-A1 | Quinoline Derivatives as Neurokinin Receptor Antagonists | MERCK SHARP & DOHME LTD. (GB) | 2008-04-24 | — | — | US | disclosed |
| EP-1776344-A2 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006013393-A2 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096885-A1 | Quinoline Derivatives as Neurokinin Receptor Antagonists | TACR3, TACR2, TAC3 | TACR3 1/4885KCNH2 61/4885PDE10A 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.